{"Clinical Trial ID": "NCT00426556", "Intervention": ["INTERVENTION 1:", "Phase I - RAD001 5mg + PT, daily", "A daily regimen of Everolimus 5mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel and Trastuzumab", "INTERVENTION 2:", "Phase I - RAD001 10mg + PT, daily", "A daily regimen of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel and Trastuzumab"], "Eligibility": ["Incorporation criteria:", "* Female or male patients 18 years of age with WHO performance status 1", "HER-2 overexpressed breast cancer metastatic cells confirmed by histology", "A progressive disease on the anterior trastuzumab alone/or in combination with other anticancers, or relapsed at any time after completion of this treatment (phase l)", "- Patient resistance to trastuzumab and taxanes (Phase ll)", "A measurable disease according to RECIST (Phase ll)", "Stable neurological patients with adequate bone marrow, hepatic and renal function", "- Exclusion criteria:", "Patients receiving endocrine treatment for breast cancer 2 weeks prior to the start of the study", "* Patients currently receiving chemotherapy, immunotherapy or radiotherapy or who received these 4 weeks prior to the start of the study or patients who received lapatinib 2 weeks prior to the start of the study", "Patients who have previously received mTOR inhibitors", "Other inclusion/exclusion criteria defined by the Protocol may apply."], "Results": ["Performance measures:", "Phase II: Overall response rate", "The primary objective of this Phase II study was to assess the efficacy of the recommended dose/regime level of everolimus from Phase I with trastuzumab and paclitaxel (PT) in patients with metastatic breast cancer overexpressing HER2 whose disease progressed on/after trastuzumab mono- and/or combination according to the objective response rate (ORR) assessment criteria for solid tumour response (RECIST). Objective response rate (ORR) was defined as the proportion of patients with the best overall response (OR) of a complete (CR) or partial response (PR). Only patients with measurable disease (presence of at least one measurable injury) to inclusion in the study.", "Time limit: every 8 to 9 weeks until the progression of the disease or a new lesion is identified", "Results 1:", "Title of arm/group: Phase I - RAD001 5mg + PT, daily", "Description of the arm/group: daily regimen of Everolimus 5mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel and Trastuzumab", "Total number of participants analysed: 0", "Type of measurement: Number", "Unit of measure: Percentage of participants", "Results 2:", "Title of arm/group: Phase I - RAD001 10mg + PT, daily", "Description of the arm/group: daily regimen of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel and Trastuzumab", "Total number of participants analysed: 0", "Type of measurement: Number", "Unit of measure: Percentage of participants"], "Adverse Events": ["Undesirable Events 1:", "Total: 3/6 (50%)", "Febrile neutropenia 0/6 (0.00 %)", "Leucopenia 0/6 (0.00 %)", "Neutropenia 0/6 (0.00 %)", "Thrombocytopenia 0/6 (0.00 %)", "Cardiorespiratory arrest 0/6 (0.00 %)", "Cardiopulmonary failure 0/6 (0.00 %)", "Vertigo 0/6 (0.00 %)", "Visual impairment 0/6 (0.00 %)", "Abdominal pain 0/6 (0.00 %)", "Diarrhoea 0/6 (0.00 %)", "- Dysphagia 0/6 (0.00 %)", "Gastric ulcer 0/6 (0.00 %)", "Adverse Events 2:", "Total: 6/17 (35.29 per cent)", "Febrile neutropenia 0/17 (0.00 %)", "Leucopenia 0/17 (0.00 %)", "Neutropenia 0/17 (0.00 %)", "Thrombocytopenia 0/17 (0.00 %)", "Cardiorespiratory arrest 1/17 (5.88 %)", "Cardiopulmonary failure 0/17 (0.00 %)", "Vertigo 0/17 (0.00 %)", "Visual impairment 0/17 (0.00 %)", "Abdominal pain 0/17 (0.00 %)", "Diarrhoea 1/17 (5.88 per cent)", "- Dysphagia 0/17 (0.00 %)", "Gastric Ulcer 1/17 (5.88 per cent)"]}